In Reply We thank Sanchez and Furberg for their thoughtful comments in response to our recent article in JAMA Oncology on the association between body mass index (BMI) and overall survival with immune checkpoint inhibitor therapy for patients with advanced non–small cell lung cancer.1 We agree that the association of body size with survival outcomes in patients with advanced cancer is complex and evolving.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kichenadasse G, Hopkins AM, Sorich MJ. Obesity Paradox in Patients With Non–Small Cell Lung Cancer Treated With Immunotherapy—Reply. JAMA Oncol. 2020;6(6):941–942. doi:10.1001/jamaoncol.2020.0643
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: